Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Rhythm Pharmaceuticals, Inc.

< Previous 1 2 3 4 Next >
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback